This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

New Data From Epratuzumab To Be Presented At EULAR 2013

MORRIS PLAINS, N.J., June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that Immunomedics and UCB (Euronext Brussels:UCB), a global biopharmaceutical company with a focus on immunology treatment and research, will present new data for their investigational studies of epratuzumab in systemic lupus erythematosus (SLE) at the European League Against Rheumatism (EULAR) 2013 Congress to be held in Madrid, Spain, from June 12 – 15, 2013.

Epratuzumab is an investigational medicine in development for the treatment of SLE. It is the first monoclonal antibody targeting CD22, a B-cell-specific protein that regulates B-cell activity. 1,2 Epratuzumab is not licensed in SLE.

Following is a guide to the investigational studies of epratuzumab for SLE being presented as oral presentations or posters at EULAR.

1. [OP0118]: Epratuzumab Mediates BCR-Antigen Trogocytosis As Potential Mechanism Of Action In Systemic Lupus Erythematosus (SLE) Goldenberg, D. et al.

  • Date/Time: June 13, 2013; 1120; Room N118
  • Session Info: Oral, Scientific Session

2. [THU0045]: Epratuzumab, An Antibody Targeting CD22 On B Cells, Induces Phosphoprotein Changes Following B-Cell Receptor Activation In Vitro Lumb, S. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Tour, Poster Area

3. [THU0277]: Epratuzumab: Sustained Safety Profile And Effect On Corticosteroid Use On Long-Term Treatment In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008) Wallace, D. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

4. [THU0272]: Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study (SL0008) Gordon, C. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

5. [THU0286]: Immunologic Response To Long-Term Epratuzumab Treatment In SL0008, An Open-Label Longterm Extension Study In Patients With Moderate-To-Severe Systemic Lupus Erythematosus Strand, V. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

6. [THU0029]: Epratuzumab Influences BCR Signalling On TLR9 Pre-Activated B Cells By Targeting CD22 Sieger, N. et al.

  • Date/Time: June 13, 2013; 1145-1330
  • Session Info: Poster Session, Poster Area

References

1. Sanz I., Eun-Hyung Lee F. B cells as therapeutic targets in SLE. Rheumatology; Vol. 6. 2010; Pp 326-327.

Stock quotes in this article: IMMU 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,433.97 +9.12 0.06%
S&P 500 1,868.46 +6.15 0.33%
NASDAQ 4,107.5010 +21.2760 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs